Compare Dover Corp (DOV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Dover Corp trades at $193.04 (market cap $25.92B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Dover Corp is far larger — about 5.3× Travere Therapeutics Inc. Common Stock's market cap, and Dover Corp pays a 1.09% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 74 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DOV | TVTX | |
|---|---|---|
Market Cap | $25.92B | $4.88B |
Volume | 807,452 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $233.31 | $67.52 |
52-Week Low | $162.66 | $26.79 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $27.43B | $5.01B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $193.33, up 1.28% with strong analyst consensus of 19 Buy ratings and no Sell recommendations. The stock shows solid fundamentals with consistent earnings beats, 13.48% net margin, and robust cash flow. Recent acquisitions and product launches position the company for growth, while technical indicators suggest neutral momentum near key resistance at $195.
Outlook remains positive with 67.9% analyst Buy rating and $243.20 price target representing 26% upside. Risks include integration challenges from recent acquisitions and industrial sector volatility. The company's Dividend King status and strong balance sheet provide stability amid market fluctuations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
